Zacks Investment Research downgraded shares of Pharma Mar (OTCMKTS:PHMMF) from a hold rating to a sell rating in a research report sent to investors on Saturday, August 4th.
According to Zacks, “Pharma Mar SA is a biopharmaceutical company. It engaged in the discovery and development of marine-derived anticancer drugs. The company’s product pipeline consists of PM1183, plitidepsin, and PM184 which are in clinical trial stage. It operates primarily in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. Pharma Mar SA is headquartered in Madrid, Spain. “
Separately, ValuEngine upgraded shares of Pharma Mar from a sell rating to a hold rating in a report on Wednesday, May 2nd.
Shares of Pharma Mar traded down $0.16, reaching $1.72, during mid-day trading on Friday, according to MarketBeat. The company had a trading volume of 208 shares, compared to its average volume of 1,912. Pharma Mar has a fifty-two week low of $1.64 and a fifty-two week high of $4.57.
About Pharma Mar
Pharma Mar, SA, a biopharmaceutical company, engages in the discovery and development of marine-derived anticancer drugs in Spain and internationally. The company operates through two segments, Biopharmaceuticals and Consumer Chemicals. It develops and commercializes YONDELIS, an antitumor agent for the treatment of advanced soft tissue sarcomas and for relapsed ovarian cancer.
Featured Story: Trading Strategy Methods for Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with MarketBeat.com's FREE daily email newsletter.